{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:39:56Z","timestamp":1792435196233,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hubei Provincial Natural Science Foundation Innovation and Development Joint Fund Project","award":["No.2024AFD422"],"award-info":[{"award-number":["No.2024AFD422"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82270177"],"award-info":[{"award-number":["No.82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16547-5","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:05:38Z","timestamp":1784217938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serglycin-ROS axis mediates synergistic lethality of PI3K\u03b3 inhibition and Azacitidine in TP53-mutated AML"],"prefix":"10.1186","volume":"26","author":[{"given":"Guiqin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-2642","authenticated-orcid":false,"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"16547_CR1","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/blood.2024025834","volume":"144","author":"M Goldfinger","year":"2024","unstructured":"Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, et al. A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024;144:2360\u20133.","journal-title":"Blood"},{"key":"16547_CR2","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39:1584\u201394.","journal-title":"J Clin Oncol"},{"key":"16547_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019;9:370\u201383.","journal-title":"Cancer Discov"},{"key":"16547_CR4","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023;41:4893\u2013904.","journal-title":"J Clin Oncol"},{"key":"16547_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","volume":"14","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Amin MK, Daver NG, Shah MV, Hiwase D, Arber DA, et al. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024;14:202.","journal-title":"Blood Cancer J"},{"key":"16547_CR6","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu H, Chen C, Hou ZS, He XD, Xie S, Ni J, et al. PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024;143:1965\u201379.","journal-title":"Blood"},{"key":"16547_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","volume":"19","author":"N Vasan","year":"2022","unstructured":"Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol. 2022;19:471\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"16547_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","volume":"5","author":"P Foubert","year":"2017","unstructured":"Foubert P, Kaneda MM, Varner JA. PI3K\u03b3 Activates Integrin \u03b1(4) and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. Cancer Immunol Res. 2017;5:957\u201368.","journal-title":"Cancer Immunol Res"},{"key":"16547_CR9","doi-asserted-by":"crossref","unstructured":"N\u00fcrnberg B, Beer-Hammer S, Function. Regulation and Biological Roles of PI3K\u03b3 Variants. Biomolecules. 2019;9(9):427.","DOI":"10.3390\/biom9090427"},{"key":"16547_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0968-0004(02)02166-7","volume":"27","author":"LD Mayo","year":"2002","unstructured":"Mayo LD, Donner DB, The PTEN. Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci. 2002;27:462\u20137.","journal-title":"Trends Biochem Sci"},{"key":"16547_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1042\/BST20140070","volume":"42","author":"AG Abraham","year":"2014","unstructured":"Abraham AG, O\u2019Neill E. PI3K\/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans. 2014;42:798\u2013803.","journal-title":"Biochem Soc Trans"},{"key":"16547_CR12","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"16547_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-018-0682-x","volume":"37","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xie X, Wu A, Wang L, Hu Y, Zhang H, Li Y. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37:12.","journal-title":"J Exp Clin Cancer Res"},{"key":"16547_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","volume":"12","author":"S Gu","year":"2023","unstructured":"Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12:23.","journal-title":"Exp Hematol Oncol"},{"key":"16547_CR15","doi-asserted-by":"publisher","first-page":"e75136","DOI":"10.1371\/journal.pone.0075136","volume":"8","author":"H Han","year":"2013","unstructured":"Han H, Yang X, Pandiyan K, Liang G. Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells. PLoS ONE. 2013;8:e75136.","journal-title":"PLoS ONE"},{"key":"16547_CR16","first-page":"656","volume":"52","author":"L Handschuh","year":"2018","unstructured":"Handschuh L, Ka\u017amierczak M, Milewski MC, G\u00f3ralski M, \u0141uczak M, Wojtaszewska M, et al. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR. Int J Oncol. 2018;52:656\u201378.","journal-title":"Int J Oncol"},{"key":"16547_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/bloodadvances.2024012995","volume":"9","author":"J Lykins","year":"2025","unstructured":"Lykins J, Becker IC, Camacho V, Alfar HR, Park J, Italiano J, Whiteheart SW. Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow. Blood Adv. 2025;9:15\u201328.","journal-title":"Blood Adv"},{"key":"16547_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jcb.29336","volume":"121","author":"L Peng","year":"2020","unstructured":"Peng L, Zhang Y, Xin H. lncRNA SNHG3 facilitates acute myeloid leukemia cell growth via the regulation of miR-758-3p\/SRGN axis. J Cell Biochem. 2020;121:1023\u201331.","journal-title":"J Cell Biochem"},{"key":"16547_CR19","doi-asserted-by":"crossref","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176:1265-81.e24.","DOI":"10.1016\/j.cell.2019.01.031"},{"key":"16547_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"16547_CR21","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhou H, Xu J, Wang J, Niu T. Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2022;13:1070660.","journal-title":"Front Immunol"},{"key":"16547_CR22","first-page":"5887","volume":"13","author":"M Park","year":"2023","unstructured":"Park M, Ha J, Lee Y, Kwon Y, Choi SH, Kim BS, Jeong YK. BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2\/M arrest, apoptosis, and senescence in a p53-independent manner. Am J Cancer Res. 2023;13:5887\u2013900.","journal-title":"Am J Cancer Res"},{"key":"16547_CR23","doi-asserted-by":"crossref","unstructured":"Sk\u00e5nland SS, Okkenhaug K, Davids MS. PI3K Inhibitors in Hematology: When One Door Closes\u2026 Clin Cancer Res. 2024;30:3667-75.","DOI":"10.1158\/1078-0432.CCR-24-0967"},{"key":"16547_CR24","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, et al. Eganelisib, a First-in-Class PI3K\u03b3 Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1\/1b MARIO-1 Trial. Clin Cancer Res. 2023;29:2210\u20139.","journal-title":"Clin Cancer Res"},{"key":"16547_CR25","doi-asserted-by":"crossref","unstructured":"Kelly LM, Rutter JC, Lin KH, Ling F, Duchmann M, Latour E et al. Targeting a lineage-specific PI3K\u0263-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. Nat Cancer. 2024;5(7):1082\u2013101.","DOI":"10.1038\/s43018-024-00782-5"},{"key":"16547_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1021\/acs.jmedchem.1c01153","volume":"65","author":"G Mata","year":"2022","unstructured":"Mata G, Miles DH, Drew SL, Fournier J, Lawson KV, Mailyan AK, et al. Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase \u03b3 (PI3K\u03b3). J Med Chem. 2022;65:1418\u201344.","journal-title":"J Med Chem"},{"key":"16547_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41401-023-01166-8","volume":"45","author":"DY Gu","year":"2024","unstructured":"Gu DY, Zhang MM, Li J, Zhou YB, Sheng R. Development of PI3K\u03b3 selective inhibitors: the strategies and application. Acta Pharmacol Sin. 2024;45:238\u201347.","journal-title":"Acta Pharmacol Sin"},{"key":"16547_CR28","doi-asserted-by":"crossref","unstructured":"O\u2019Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024;12(8):e009160.","DOI":"10.1136\/jitc-2024-009160"},{"key":"16547_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","volume":"630","author":"Q Luo","year":"2024","unstructured":"Luo Q, Raulston EG, Prado MA, Wu X, Gritsman K, Whalen KS, et al. Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling. Nature. 2024;630:198\u2013205.","journal-title":"Nature"},{"key":"16547_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","volume":"138","author":"M Li","year":"2018","unstructured":"Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, et al. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation. 2018;138:696\u2013711.","journal-title":"Circulation"},{"key":"16547_CR31","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, et al. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat Cancer. 2022;3:837\u201351.","journal-title":"Nat Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16547-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:02:52Z","timestamp":1792432972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16547-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16547"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16547-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Peripheral blood (PB) samples were collected from AML patients and healthy donors under a protocol approved by the Institutional Review Board of Tongji Medical College, Huazhong University of Science and Technology (permit number TJ-IRB 20230228). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants or their legal guardians included in the study.The animal experiments conducted in this study were approved by the Institutional Animal Care and Use Committee of Tongji Medical College, Huazhong University of Science and Technology (Approval number: 4250). All animal procedures were performed in accordance with the specified guidelines and regulations to ensure humane treatment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1251"}}